Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy

Clinical Immunology

Volumn 108, Issue 3, 2003, Pages 211-220

  Morishima, Chihiro ^a,c   Musey, Luwy ^a   Elizaga, Marnie ^a,b   Gaba, Kersten ^a   Allison, Megan ^a   Carithers, Robert L ^a   Gretch, David R ^a   McElrath, M Juliana ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytotoxic T lymphocyte; Hepatitis C; Immune response; Interferon ; Ribavirin; T cells; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; REBETRON;

ADULT; ARTICLE; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MEMORY CELL; PREVALENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIROLOGY;

EID: 0141788724     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00142-6     Document Type: Article

References (40)

1. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:1996;706-714.
2. Lechner F., Wong D.K.H., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512.
3. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449.
4. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., Walker B.D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis [published erratum appears in J Immunol 1993 Mar 15;150(6):2563]. J. Immunol. 149:1992;3339-3344.
5. Koziel M.J., Dudley D., Afdhal N., Choo Q.L., Houghton M., Ralston R., Walker B.D. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J. Virol. 67:1993;7522-7532.
6. Rehermann B., Chang K.M., McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest. 98:1996;1432-1440.
7. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1995;1006-1007.
8. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead- Loudis J., McHutchison J.G., Alter H.J., Chisari F.V. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 33:2001;267-276.
9. Cucchiarini M., Kammer A.R., Grabscheid B., Diepolder H.M., Gerlach T.J., Gruner N., Santantonio T., Reichen J., Pape G.R., Cerny A. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell. Immunol. 203:2000;111-123.
10. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:2000;296-305.
11. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
12. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339:1998;1493-1499.
13. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 118:2000;346-355.
14. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., Hoffmann R., Schirren C.A., Santantonio T., Pape G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology Oct. 117:1999;933-941.
15. Hoffmann R.M., Diepolder H.M., Zachoval R., Zwiebel F.M., Jung M.C., Scholz S., Nitschko H., Riethmuller G., Pape G.R. Mapping of immunodominant CD4(+) T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology. 21:1995;632-638.
16. Lasarte J.J., GarciaGranero M., Lopez A., Casares N., Garcia N., Civeira M.P., BorrasCuesta F., Prieto J. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 28:1998;815-822.
17. Lohr H.F., Gerken G., Roth M., Weyer S., Schlaak J.F., zum Buschenfelde K.H. The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J. Hepatol. 29:1998;524-532.
18. Rehermann B., Chang K.M., McHutchinson J., Kokka R., Houghton M., Rice C.M., Chisari F.V. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 70:1996;7092-7102.
19. Lohr H.F., Schmitz D., Arenz M., Weyer S., Gerken G., zum B.-K.H.M. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J. Hepatol. 31:1999;407-415.
20. Barnes E., Harcourt G., Brown D., Lucas M., Phillips R., Dusheiko G., Klenerman P. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology. 36:2002;743-754.
21. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., Canella A., Marino M., Tomatis R., Traniello S., Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32:2002;144-154.
22. Fang J.W., Albrecht J.K., Jacobs S., Lau J.Y. Quantification of serum hepatitis C virus RNA. Hepatology. 29:1999;997-998.
23. Davidson F., Simmonds P., Ferguson J.C., Jarvis L.M., Dow B.C., Follett E.A., Seed C.R., Krusius T., Lin C., Medgyesi G.A., et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J. Gen. Virol. 76:1995;1197-1204.
24. Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M.J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection [see comments]. N. Engl. J. Med. 337:1997;1267-1274.
25. Musey L., Hu Y., Eckert L., Christensen M., Karchmer T., McElrath M.J. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J. Exp. Med. 185:1997;293-303.
26. Leroux-Roels G., Esquivel C.A., DeLeys R., Stuyver L., Elewaut A., Philippe J., Desombere I., Paradijs J., Maertens G. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology. 23:1996;8-16.
27. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., Reiser M., Kim A.Y., Lucas M., Klenerman P., Walker B.D. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76:2002;6104-6113.
28. Koziel M.J., Dudley D., Afdhal N., Grakoui A., Rice C.M., Choo Q.L., Houghton M., Walker B.D. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J. Clin. Invest. 96:1995;2311-2321.
29. Wong D.K.H., Dudley D.D., Dohrenwend P.B., Lauer G.M., Chung R.T., Thomas D.L., Walker B.D., Patzwahl R., Meier V., Ramadori G., Mihm S. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J. Virol. 75:2001;1229-1235.
30. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J.L., Manns M.P., Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. May. 6:2000;578-582.
31. Lancaster T., Sanders E., Christie J.M., Brooks C., Green S., Rosenberg W.M. Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J. Viral Hepat. 9:2002;18-28.
32. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., Sallie R., Park Y., Yurdaydin C., Swain M., Kleiner D.E., Mahaney K., Hoofnagle J.H. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123:1995;897-903.
33. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., Rassam S., Fryden A., Reesink H., Bassendine M., Norkrans G., Cuypers T., Lelie N., Telfer P., Watson J., Weegink C., Sillikens P., Weiland O. Ribavirin treatment for patients with chronic hepatitis C results of a placebo-controlled study . J. Hepatol. 25:1996;591-598.
34. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30:1999;376-382.
35. Fang S.H., Hwang L.H., Chen D.S., Chiang B.L. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J. Hepatol. 33:2000;791-798.
36. Lau J.Y., Tam R.C., Liang T.J., Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 35:2002;1002-1009.
37. Hultgren C., Milich D.R., Weiland O., Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79:1998;2381-2391.
38. Heagy W., Crumpacker C., Lopez P.A., Finberg R.W. Inhibition of immune functions by antiviral drugs. J. Clin. Invest. 87:1991;1916-1924.
39. Jiang Z., Kunimoto M., Patel J.A. Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. J. Virol. 72:1998;2496-2499.
40. Mastronarde J.G., Monick M.M., Gross T.J., Hunninghake G.W. Amiloride inhibits cytokine production in epithelium infected with respiratory syncytial virus. Am. J. Physiol. 271:1996;L201-207.